Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 219

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 219
---
 are scheduled to vest on a quarterly basis over 2 years in equal quarterly instalments of 10,000 options, beginning with the quarter ended March 31, 2024. The options are exercisable within eight years from the grant date. The aggregate grant date fair value of such options was approximately $190. |

| b. | On November 11, 2024, following discussions with the management of the Company, the Board has determined                                      
 that it is advisable and in the best interests of the Company and its stockholders to further amend the Plan, as amended (“Amendment          
 #2”), to reduce the maximum number of shares reserved for issuance under the Plan from 20,000,000 shares of Common Stock to 10,000,000        
 shares of Common Stock. Amendment No. 2 became effective on the date of the approval by the Board of Directors, but it is subject to approval 
 by the Company’s shareholders within 12 months, pursuant to section 422(b)(1) of the Internal Revenue Code.                                   |

| c. | On December 31, 2024, the Board approved a grant under the Company’s Global Share Incentive Plan                                            
 (2021) to an employee of the Predecessor of 740,000 stock options at an exercise price of $0.30 per share. Of the options granted, options  
 for 560,000 shares were fully vested upon grant and the remaining 180,000 options are to be vest on April 10, 2025. The options exercisable 
 within ten years from grant date.                                                                                                           |

<div align='center'>F-27</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 8 – SHAREHOLDERS’ EQUITY (Cont.)

The fair value of the successor’s share
options granted during the period commencing July 24, 2024 through December 31, 2024 was estimated using the black Scholes model using
the following range assumptions:

| Description             |     | December 31, 
 2024         |       |   |
|:------------------------|:----|:-------------|------:|:--|
| Risk-free interest rate |     |              |  4.51 | % |
| Expected volatility     |     |              | 105.6 | % |
| Dividend yield          |     |              |